Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.85
$0.071.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.56% | 23.64% | -139.16% | 306.21% | -8.54% |
| Total Depreciation and Amortization | -4.34% | 0.00% | -1.86% | -21.50% | -5.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.04% | -42.51% | -16.98% | 16.52% | 29.89% |
| Change in Net Operating Assets | 89.35% | -410.73% | -327.08% | 94.17% | -59.84% |
| Cash from Operations | 8.97% | 12.12% | -132.38% | 332.95% | -9.18% |
| Capital Expenditure | -- | -1,115.79% | -- | 100.00% | 63.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -131.19% | -42.98% | 134.93% | -132.78% | 107.02% |
| Cash from Investing | -134.38% | -48.05% | 134.78% | -132.81% | 107.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -86.93% | 68.44% | -77.17% | 475.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -86.93% | 68.44% | -77.17% | 475.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.21% | -2.35% | -130.12% | 222.65% | 420.90% |